Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT ...Middle East

SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1...

Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT )

Also on site :

• Bodies of two Israeli-American hostages recovered from Gaza in joint military operation
• Second interview with AUC professor Bahgat Korany discusses Suez Canal, GERD concerns & global politics
• Philadelphia Cream Cheese Shakes Up Classic Recipe With Limited-Edition Offer